Biologics Market Size, Share, Trends, Growth Outlook

Biologics Market is estimated to increase at a growth rate of 11.5% CAGR over the forecast period from 2024 to 2030.

The Biologics Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Product (Monoclonal Antibodies, Vaccines, Recombinant Hormones/Proteins, Cellular-based Biologics, Gene-based Biologics, Others), By Application (Cancer, Infectious Diseases, Autoimmune Diseases, Others).

An Introduction to Biologics Market in 2024

The Biologics market in 2024 continues to thrive as a cornerstone of modern medicine, with biopharmaceuticals revolutionizing the treatment landscape for various chronic and complex diseases. Biologics, including monoclonal antibodies, recombinant proteins, and cell-based therapies, offer targeted mechanisms of action, improved efficacy, and reduced adverse effects compared to conventional small-molecule drugs. Expanding therapeutic indications, patent expirations of blockbuster biologics, and biosimilar competition drive market dynamics, fostering innovation and market access initiatives by pharmaceutical companies. Regulatory agencies focus on ensuring the safety, efficacy, and quality of biologic products, while healthcare systems grapple with reimbursement challenges and access disparities, underscoring the need for sustainable pricing models and equitable distribution strategies to optimize patient care.

Biologics Market Trend: Increasing Adoption of Personalized Medicine

A prominent trend in the Biologics market is the increasing adoption of personalized medicine. As advancements in genomics and molecular biology continue to unravel the complexities of disease mechanisms, there is a growing emphasis on tailoring treatment strategies to individual patient characteristics, including genetic makeup, biomarker profiles, and disease phenotypes. Biologics, with their ability to target specific molecular pathways and modulate immune responses, are well-suited for personalized therapeutic approaches. This trend is driving the development of novel biologic therapies with enhanced targeting capabilities, improved efficacy, and reduced adverse effects, thereby paving the way for precision medicine in various disease areas such as oncology, autoimmune disorders, and rare diseases.

Biologics Market Driver: Rising Burden of Chronic and Autoimmune Diseases

The primary driver for the Biologics market is the rising burden of chronic and autoimmune diseases. With the global prevalence of conditions such as cancer, rheumatoid arthritis, inflammatory bowel disease, and psoriasis on the rise, there is an escalating demand for effective therapeutic interventions that can provide sustained disease control and symptom relief. Biologics offer targeted treatment options that address underlying disease mechanisms, leading to better outcomes and improved quality of life for patients. Moreover, the expanding pipeline of biologic drugs, coupled with advancements in bioprocessing technologies and manufacturing capabilities, is facilitating the development and commercialization of innovative biologic therapies, further driving market growth.

Biologics Market Opportunity: Expansion into Biosimilars Market Segment

An opportunity in the Biologics market lies in the expansion into the biosimilars market segment. With several blockbuster biologic drugs approaching patent expiry, there is a significant opportunity for companies to enter the biosimilars market and offer more affordable alternatives to branded biologic therapies. Biosimilars, which are highly similar but not identical to reference biologics, have the potential to increase patient access to life-saving treatments while generating cost savings for healthcare systems. By leveraging their expertise in bioprocessing, regulatory compliance, and supply chain management, biopharmaceutical companies can capitalize on the growing demand for biosimilars and establish a competitive presence in this rapidly evolving market segment. Investing in biosimilars development and commercialization presents a strategic opportunity for stakeholders in the Biologics market to expand their product portfolios, penetrate new market segments, and drive revenue growth in the long term.

Biologics Market Segmentation

By Product
Monoclonal Antibodies
Vaccines
Recombinant Hormones/Proteins
Cellular-based Biologics
Gene-based Biologics
Others
By Application
Cancer
Infectious Diseases
Autoimmune Diseases
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Biologics Market Companies

AbbVie Inc
Amgen Inc
Bristol-Myers Squibb Company
Celltrion Healthcare Co. Ltd
Eli Lilly and Company
F. Hoffmann La-Roche Ltd
Johnson & Johnson Services Inc
Novo Nordisk A/S
Samsung Biologics
Sanofi

 

 

Reasons to Buy the Biologics Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Biologics Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Biologics Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

 

TABLE OF CONTENTS

1 Introduction to 2024 Biologics Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Biologics Market Size Outlook, $ Million, 2021 to 2030
3.2 Biologics Market Outlook by Type, $ Million, 2021 to 2030
3.3 Biologics Market Outlook by Product, $ Million, 2021 to 2030
3.4 Biologics Market Outlook by Application, $ Million, 2021 to 2030
3.5 Biologics Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Biologics Market Industry
4.2 Key Market Trends in Biologics Market Industry
4.3 Potential Opportunities in Biologics Market Industry
4.4 Key Challenges in Biologics Market Industry

5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Biologics Market Share by Company (%), 2023
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Biologics Market Outlook By Segments
7.1 Biologics Market Outlook by Segments
By Product
Monoclonal Antibodies
Vaccines
Recombinant Hormones/Proteins
Cellular-based Biologics
Gene-based Biologics
Others
By Application
Cancer
Infectious Diseases
Autoimmune Diseases
Others

8 North America Biologics Market Analysis And Outlook To 2030
8.1 Introduction to North America Biologics Markets in 2024
8.2 North America Biologics Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Biologics Market size Outlook by Segments, 2021-2030
By Product
Monoclonal Antibodies
Vaccines
Recombinant Hormones/Proteins
Cellular-based Biologics
Gene-based Biologics
Others
By Application
Cancer
Infectious Diseases
Autoimmune Diseases
Others

9 Europe Biologics Market Analysis And Outlook To 2030
9.1 Introduction to Europe Biologics Markets in 2024
9.2 Europe Biologics Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Biologics Market Size Outlook By Segments, 2021-2030
By Product
Monoclonal Antibodies
Vaccines
Recombinant Hormones/Proteins
Cellular-based Biologics
Gene-based Biologics
Others
By Application
Cancer
Infectious Diseases
Autoimmune Diseases
Others

10 Asia Pacific Biologics Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Biologics Markets in 2024
10.2 Asia Pacific Biologics Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Biologics Market size Outlook by Segments, 2021-2030
By Product
Monoclonal Antibodies
Vaccines
Recombinant Hormones/Proteins
Cellular-based Biologics
Gene-based Biologics
Others
By Application
Cancer
Infectious Diseases
Autoimmune Diseases
Others

11 South America Biologics Market Analysis And Outlook To 2030
11.1 Introduction to South America Biologics Markets in 2024
11.2 South America Biologics Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Biologics Market size Outlook by Segments, 2021-2030
By Product
Monoclonal Antibodies
Vaccines
Recombinant Hormones/Proteins
Cellular-based Biologics
Gene-based Biologics
Others
By Application
Cancer
Infectious Diseases
Autoimmune Diseases
Others

12 Middle East And Africa Biologics Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Biologics Markets in 2024
12.2 Middle East and Africa Biologics Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Biologics Market size Outlook by Segments, 2021-2030
By Product
Monoclonal Antibodies
Vaccines
Recombinant Hormones/Proteins
Cellular-based Biologics
Gene-based Biologics
Others
By Application
Cancer
Infectious Diseases
Autoimmune Diseases
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AbbVie Inc
Amgen Inc
Bristol-Myers Squibb Company
Celltrion Healthcare Co. Ltd
Eli Lilly and Company
F. Hoffmann La-Roche Ltd
Johnson & Johnson Services Inc
Novo Nordisk A/S
Samsung Biologics
Sanofi

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product
Monoclonal Antibodies
Vaccines
Recombinant Hormones/Proteins
Cellular-based Biologics
Gene-based Biologics
Others
By Application
Cancer
Infectious Diseases
Autoimmune Diseases
Others